News

Mayo Clinic Laboratories and Lucence are expanding access to advanced cancer testing worldwide with LiquidHALLMARK®, a next-generation liquid biopsy that provides actionable genomic insights. This collaboration empowers physicians to deliver personalized care and improve patient outcomes.

Due to a pending winter storm affecting the FedEx hub in Memphis, Tennessee, and the UPS hub in Louisville, Kentucky, Mayo Clinic Laboratories will monitor and track the situation with our logistics partners to minimize challenges. Read more for updates.

As Winter Storm Blair moves through the Midwest and East Coast, Mayo Clinic Laboratories will monitor and track the situation with our logistics partners to minimize challenges. If any routes are modified or canceled, clients in the affected areas will be contacted directly.

Mayo Clinic Laboratories is grateful for your collaboration in 2024.

Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered for the New Year's holiday. To ensure specimen viability and minimize delays, the following adjustments and guidelines have been implemented and will be communicated to clients and couriers today. 

Five of the most significant advancements from Mayo Clinic Laboratories in 2024 to enhance diagnostics and patient care globally.

Dr. Morice highlights the crucial role of hospital-owned laboratories in enhancing patient care and hospital operations.

Due to the Christmas holiday (recognized on Wednesday, Dec. 25), Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered. To ensure specimen stability and prevent delays, follow the guidelines outlined below for domestic clients and international clients.

Kelly DuBois recently joined “Symptomatic: A Medical Mystery Podcast” to explain her health journey with Mayo Clinic. In the episode, Kelly, who faced a series of unexplained health issues over two decades, highlighted the help that Mayo Clinic was able to offer her after being misdiagnosed with acromegaly.

Mayo Clinic Laboratories (MCL) is pleased to announce an essential update to our CPT code communication process and website layout. This change is designed to bring timely notifications for accurate billing information.

New diagnostic tests specifically for conditions that predominantly or only affect women, such as autoimmune diseases and gynecological cancers, are empowering female patients and their physicians to make informed decisions.

The Lupus Foundation of America estimates that at least five million people worldwide have a form of lupus. Yet, the most widely used laboratory tests for patients with this complex condition were developed more than 60 years ago, and physicians need modern, evidence-based tools to provide high-quality care for their patients. That is why Mayo Clinic Laboratories and Progentec Diagnostics joined forces to provide solutions that transform that experience.

Mayo Clinic researchers identify a new subtype of MGTS, linked to recurrent blood clots, with significant diagnostic challenges and treatment implications.